September 2018
Dear Colleague,
Welcome to the September 2018 edition of our Updates on Myeloproliferative Neoplasms (MPNs) newsletter. This month, we highlight two articles on polycythemia vera concerning the role of JAK2 inhibition and cytoreductive therapy. We also explore myelofibrosis news, including ruxolitinib dose escalation to decrease adverse events and the potential of PTX3 plasma levels in determining disease burden. Additionally, we feature news articles on a new tool for patients with myelofibrosis undergoing stem cell transplantation and a study showing an increased risk of disease among relatives of patients with myeloid blood cancers.
And don’t forget about our other valuable MPN resources:
- Watch me and three experts in the field discuss the current state of MPN treatment and management through three case studies in our roundtable panel discussion, “Management of Myeloproliferative Neoplasms: A Case-Based Discussion.”
- Learn more about MPN diagnosis and long-term management from the patient perspective in my interview with Samantha—a patient of mine who has been managing her disease for the past 15 years.
- Check out our helpful “fast facts” guides, which provide information on MPN incidence and mortality data and World Health Organization diagnostic criteria.
As always, I hope you find this month’s newsletter insightful and helpful for your everyday practice and beyond.
Please feel free to share this newsletter with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at editor@advancedpractitioner.com at any time.
Lindsey Lyle, MS, PA-C
Instructor, Medicine-Hematology
University of Colorado, Anschutz Medical Campus
